Recon: BMS, Pfizer to sell Eliquis direct to patients at a discount; Sarepta to layoff 500 staff as it adds boxed warning for DMD gene therapy

• Senators reveal how much Lilly, Pfizer paid telehealth companies (STAT)
• FDA advisers vote against combination therapies of GSK's blood cancer drug (Reuters)
• Bristol-Myers and Pfizer to Offer Blockbuster Blood Thinner at Discount (The Wall Street Journal)
• Trump’s Medicare agency to speed up clawback of $7.8 billion in hospital drug payments (STAT)
• RFK Jr.’s FDA may take cues on stem cells from red-state laws, clinic doctors (STAT)
• House Bill Seeks to Help Veterans Access Alternatives to Opioids (Bloomberg)
• Sarepta adds black box warning to its Duchenne treatment, cuts 500 workers (Endpoints) (Reuters)
• Blood Pressure Rising: FDA Warning Letter Takes an Aggressive Approach on General Wellness Product (FDA Law Blog)

• Novo Nordisk Owner Buys Microsoft Quantum Computer With Denmark (Bloomberg)
• UK HRA Sets Targets For Digital Overhaul, Trial Transparency & Trust (MedTech Insight)
• Valneva Expects UK & France to Lift Ixchiq Age Restriction Following EMA Decision (MedTech Insight)
• Trump’s U-Turn on Nvidia Spurs Talk of Grand Bargain With China (Bloomberg)

• Could weight loss drugs like Ozempic help combat addiction? (STAT)
• Boots Increases Dollar Loan Offering, Further Trims Bond Size (Bloomberg)
• Novartis Drops as CFO Plans Retirement, Cosentyx Disappoints (Bloomberg) (Reuters)
• Pfizer penicillin recall imperils syphilis treatment supply, particularly for pregnant women (Endpoints)
• Massive proteomics study reveals new clues about Alzheimer’s and rekindles old ones (Endpoints)
• BioNTech's strategy chief, who led deals to reshape company, will leave in September (Endpoints)
• Three-person IVF technique spared children from inherited diseases, scientists say (Reuters)

• US FDA approves pre-filled version of GSK's shingles vaccine (Reuters)
• Medicare plans to cover more than a thousand new procedures in outpatient settings, despite concerns about safety (STAT)
• Thermo Fisher buys Sanofi factory; Amphastar Pharma quadruples HQ capacity (Endpoints)
• Abbott Drops on Outlook Cut, Sees $200 Million Tariff Impact (Bloomberg) (Reuters)
• Otsuka/Lundbeck’s Rexulti PTSD Claim Will Test US FDA AdComm’s Supportive Evidence Flexibility (MedTech Insight)

• FDA revoking ‘Standards of Identity’ for more than 50 foods (Food Safety News)
• Trump says Coca-Cola to switch to cane sugar in U.S. — just like Mexican Coke (The Washington Post)
• FMI Urges FDA to Revise Food Traceability Rule as Part of Agency’s Deregulation Efforts (Food Safety Magazine)

• FDA Authorizes Juul’s E-Cigarettes, Reversing Ban That Nearly Bankrupted Firm (WSJ) (Reuters)
• Study finds no evidence aluminum salts in vaccines are tied to higher risk of asthma, other childhood diseases (STAT)
• Kennedy dismisses two top HHS aides (STAT)
• Medical research participants deserve to be paid well (STAT)
• Stop Playing Whac-a-Mole With Forever Chemicals (Bloomberg)
• Senate Bill Would Hasten Health Data From Insurers to Employers (Bloomberg)
• FDA hits Daewoo Pharma with warning letter over potentially poisonous contaminants (Endpoints)
• FDA drugs center sees sharp rise in staff departures since January (Endpoints)
• Elevance cuts forecast as rising costs hit health insurers (Reuters)